National Health (Listed drugs on F1 or F2) Amendment Determination 2013 (No. 2) (No. PB 19 of 2013)

Link to law: https://www.comlaw.gov.au/Details/F2013L00575

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
 
PB 19 of 2013
 
National Health (Listed drugs on F1 or F2) Amendment Determination 2013 (No. 2)1
National Health Act 1953
I, ADRIANA PLATONA, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the
Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.
Dated          27               March   2013
 
 
 
 
 
 
 
 
 
ADRIANA PLATONA
 
Assistant Secretary
Pharmaceutical Evaluation Branch
Pharmaceutical Benefits Division
Department of Health and Ageing
 
 
 
Part 1         Preliminary
1              Name of Determination
         (1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2013 (No. 2).
         (2)   This Determination may also be cited as PB 19 of 2013.
2              Commencement
                This Determination commences on 1 April 2013.
3              Amendment of National Health (Listed drugs on F1 or F2) Determination 2010
                Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).
Schedule 1             Amendments
 
(Section 3)
 
[1]     Schedule 1, after item dealing with Bivalirudin
 
Insert
 
Boceprevir
 
[2]     Schedule 1, after item dealing with Calcium
 
Omit
 
Candesartan
 
[3]     Schedule 1, after item dealing with Desmopressin
 
Omit
 
Desvenlafaxine
 
 
[4]     Schedule 1, after item dealing with Domperidone
 
Omit
 
Donepezil
 
[5]     Schedule 1, after item dealing with Doxorubicin, peglyated liposomal
 
Omit
 
Duloxetine
 
[6]     Schedule 1, after item dealing with Epoprostenol
 
Omit
 
Eprosartan
 
[7]     Schedule 1, after item dealing with Interferon beta-1a
 
Omit
 
Interferon Beta-1b
 
[8]     Schedule 1, after item dealing with Interferon gamma-1b
 
Omit
 
Irbesartan
 
[9]     Schedule 1, after item dealing with Lithium
 
Omit
 
Losartan
 
[10]   Schedule 1, after item dealing with Ofloxacin
 
Omit
 
Olmesartan
 
[11]   Schedule 1, after item dealing with Rosiglitazone
 
Insert
 
Rotigotine
 
[12]   Schedule 1, after item dealing with Tadalafil
 
Insert
 
Telaprevir
 
[13]   Schedule 1, after item dealing with Telbivudine
 
Omit
 
Telmisartan
 
[14]   Schedule 1, after item dealing with Triptorelin
 
Omit
 
Tropisetron
 
[15]   Schedule 1, after item dealing with Valine with carbohydrate
 
Omit
 
Valsartan
 
[16]   Schedule 2, after item dealing with Calcitriol
 
Insert
 
Candesartan
 
[17]   Schedule 2, after item dealing with Desferrioxamine
 
Insert
 
Desvenlafaxine
 
 
[18]   Schedule 2, after item dealing with Docetaxel
 
Insert
 
Donepezil
 
[19]   Schedule 2, after item dealing with Doxycycline
 
Insert
 
Duloxetine
 
[20]   Schedule 2, after item dealing with Epirubicin
 
Insert
 
Eprosartan
 
[21]   Schedule 2, after item dealing with Indomethacin
 
Insert
 
Interferon beta-1b
 
[22]   Schedule 2, after item dealing with Ipratropium
 
Insert
 
Irbesartan
Irbesartan with Hydrochlorothiazide
 
[23]   Schedule 2, after item dealing with Loperamide
 
Insert
 
Losartan
 
[24]   Schedule 2, after item dealing with Olanzapine
 
Insert
 
Olmesartan
 
[25]   Schedule 2, after item dealing with Tamoxifen
 
Insert
 
Telmisartan
 
[26]   Schedule 2, after item dealing with Trimethoprim with sulfamethoxazole 
 
Insert
 
Tropisetron
 
[27]   Schedule 2, after item dealing with Valproic acid
 
Insert
 
Valsartan
 
 
Note
1.       All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See http://www.comlaw.gov.au.